Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 2Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Breast 1

Conditions

Thyroid Nodule 1Thyroid Neoplasms 1Thyroid Diseases 1Parathyroid Neoplasms 1Parathyroid Diseases 1Opioid-Related Disorders 1Goiter 1Agnosia 1

Interventions

Cisplatin 263Radiotherapy 166Cetuximab 159Docetaxel 105Fluorouracil 104pembrolizumab 94Radiotherapy, Intensity-Modulated 83Carboplatin 80Paclitaxel 73Nivolumab 59Erlotinib Hydrochloride 35Surveys and Questionnaires 32Gemcitabine 32durvalumab 30Radiation 29Drug Therapy 25Immunohistochemistry 21Gefitinib 21Capecitabine 21tremelimumab 18Bevacizumab 18Surgical Procedures, Operative 17Sorafenib 17Magnetic Resonance Spectroscopy 17Ipilimumab 17Pemetrexed 16lenvatinib 15atezolizumab 15Radiosurgery 15Gene Expression Profiling 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Capsules × Head & Neck × Clear all
NCT03469310 2021-05-11

Minimizing Narcotic Analgesics After Endocrine Surgery

DHR Health Institute for Research and Development

Phase 4 Completed
126 enrolled
Head & Neck

Agnosia, Goiter, Opioid-Related Disorders, Parathyroid Diseases, Parathyroid Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Thyroid Nodule

Data powered by HemOnc (CC BY 4.0) Colophon âš¡